Xarelto

Your dosage of Xarelto will depend on your specific medical condition. Typically, the recommended dose for preventing blood clots after hip or knee replacement surgery is 10 mg once daily. For stroke prevention in atrial fibrillation, the usual dose is 20 mg once daily with the evening meal. It's important to take Xarelto as prescribed by your healthcare provider and do not exceed the recommended dose. If you miss a dose, take it as soon as you remember. If it's almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.  

Xarelto contains the active ingredient rivaroxaban. Each tablet of Xarelto may contain 10 mg, 15 mg, or 20 mg of rivaroxaban. In addition to the active ingredient, Xarelto tablets may also contain excipients such as microcrystalline cellulose, croscarmellose sodium, hypromellose, lactose monohydrate, and magnesium stearate. 

Common side effects of Xarelto may include bleeding, bruising, and dizziness. Serious side effects that require immediate medical attention include signs of bleeding such as pink or brown urine, red or black stools, or coughing up blood. Allergic reactions to Xarelto are rare but seek medical help if you experience symptoms like rash, itching, swelling, severe dizziness, or trouble breathing. 

It's important to note that Xarelto is not suitable for everyone. Do not use Xarelto if you have active bleeding, a history of bleeding disorders, or severe liver disease. Pregnant women and children should also avoid using Xarelto. If you have a heart condition or are taking other blood-thinning medications, speak to your doctor before starting Xarelto to prevent potential interactions or complications. 

Package leaflet Xarelto 15 mg 20 mg film-coated tablets. (n.d.). Apotheekvoorzorg.nl. Consulted on 21 July 2021 on https://www.apotheekvoorzorg.nl/Leden/Assortiment/bijsluiters/12338.pdf 

Royal Dutch Pharmaceutical Society. (14 July 2021). Rivaroxaban. Apotheek.nl. https://www.apotheek.nl/medicijnen/rivaroxaban?product=xarelto 

Netherlands Thrombosis Foundation. (21 June 2021). What are Direct Oral Anticoagulants (DOACs)? Thrombosis Foundation. https://www.trombosestichting.nl/trombose/behandeling/doac/ 

Dutch National Health Care Institute. (n.d.). Rivaroxaban. Farmacotherapeutic Compass. Consulted on 21 July 2021 on https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/r/rivaroxaban